Venoruton® vs Daflon®: Evaluation of Effects on Quality of Life in Chronic Venous Insufficiency

Abstract

The aim of this independent study was to investigate differences in efficacy between oxerutins (Venoruton) and 500 mg micronized diosmin + hesperidin (D+H) (Daflon) in patients with chronic venous insufficiency (CVI), evaluating venous-related quality of life (Ve-QOL). A first group of 90 patients with severe venous hypertension (CVI, ankle swelling) was randomized to treatment with oxerutins or D+H. The oxerutins group received oral oxerutins (2 g/day); the D+H group received 3 (500 mg) tablets daily every 8 hours for 8 weeks. A second group of 122 comparable patients was included in a registry following the same study format. The 2 treatments were administered with the same methods and procedures. Clinical conditions were comparable. All patients completing 8 weeks of treatment were included in a registry. Specialists or general practitioners included patients when they considered that clinical conditions were compatible with treatment indications using 1 of the 2 treatments on the basis of their evaluation and experience. When cases were compatible with the registry, the prescribing physician communicated the case to our monitoring center. Patients were evaluated without interfering with their treatment. The main target of evaluation for this study was the change in Ve-QOL (range, 0-100) induced by treatment. A specific Ve-QOL questionnaire was used for this study. Ve-QOL score is a specific expression of the changes in QOL induced by CVI in patients between 35 and 75 years old (defined in our population studies) in which no other significant clinical disease is present (as a confounding factor affecting QOL). Two hundred twelve patients completed the 2 parts of the study. The 2 treatment groups were comparable for age and gender distribution. The mean age was 42 years (SD ±5.5) in the oxerutins group and 41.5 (SD ±6) in the D+H group. There were no differences in the severity of CVI between the treatment groups at inclusion. A significant decrease (46.8%, p<0.05) in Ve-QOL score; that is, improvement, was observed in the oxerutins group. The change in Ve-QOL was significantly less in the D+H group (15.5%). In conclusion, CVI, venous microangiopathy, and edema were significantly improved by the treatment with oxerutins; the improvement in QOL was significantly greater in the oxerutins group. The comparison with D+H indicates that oxerutins is comparatively more effective on Ve-QOL and on signs/symptoms of CVI

Get full access to this article

View all access options for this article.

References

Belcaro G , Rulo A , Candiani C : Evaluation of the microcirculatory effects of Venoruton in patients with chronic venous hypertension with laser Doppler flowmetry, transcutaneous PO2 and PCO2 measurements, leg volumetry and ambulatory venous pressure measurements. Phlebology 4:23-26, 1989.

Cesarone MR , Ricci A , Belcaro G , et al : Acute effect of hydroxyethylrutosides on capillary filtration in normal volunteers, patients with venous hypertension and in patients with diabetic microangiopathy (a dose-comparison study). Vasa 21:76-79, 1992.

Belcaro G , Errichi BM : Evaluation of capillary permeability in patients with venous hypertension treated with Venoruton by the vacuum suction chamber (VSC) device. Phlebologie 41:847-849, 1988.

Incandela L , Belcaro G , Renton S , et al : HR(Paroven, Venoruton; 0(beta-hydroxyethyl)-rutosides) in venous hypertensive microangiopathy: A prospective, placebo-controlled, randomized trial. J Cardiovasc Pharmacol Ther 7(suppl I):S7-S10, 2002.

Incandela L , Cesarone MR , Belcaro G , et al : Treatment of diabetic microangiopathy and edema with HR(Paroven, Venoruton; 0(beta-hydroxyethyl)-ruto-sides): A prospective, placebo-controlled, randomized study. J Cardiovasc Pharmacol Ther 7(suppl I): S11-S13, 2002.

Cesarone MR , Incandela L , De Sanctis MT , et al : Treatment of edema and increased capillary filtration in venous hypertension with HR(Paroven, Venoruton; 0(beta-hydroxyethyl)-rutosides): A clinical, prospective, placebo-controlled, randomized, dose-ranging trial. J Cardiovasc Pharmacol Ther 7(suppl I):S21-S25, 2002.

Poynard T , Valterio C : Meta-analysis of hydroxyethylrutosides in the treatment of chronic venous insufficiency. Vasa 23:244-260, 1994.

De Sanctis MT , Cesarone MR , Incandela L , et al : Methods of evaluation and quantification of microangiopathy in high perfusion microangiopathy (chronic venous insufficiency and diabetic microangiopathy). J Cardiovasc Pharmacol Ther 7(suppl I): S3-S5, 2002.

Belcaro G , Nicolaides AN , Stansby G (eds): The Venous Clinic. London: Imperial College Press, 1999.

10.

Belcaro G , Nicolaides AN (eds): Noninvasive Investigations in Vascular Disease. London: Imperial College Press, 2001.

11.

Belcaro G : The role of transcutaneous PCO2 measurements in association with laser Doppler flowmetry in venous hypertension. Phlebology 3:189-193, 1988.

12.

Belcaro G , Grigg M , Rulo A , et al : Blood flow in the perimalleolar skin in relation to posture in patients with venous hypertension. Ann Vasc Surg 1:5-8, 1989a.

13.

Belcaro G , Christopoulos D , Nicolaides AN : Skin flow and swelling in postphlebitic limbs. Vasa 18:136-138, 1989b.

14.

Belcaro G , Nicolaides AN , Volteas N , et al : Skin flow, the venoarteriolar response and capillary filtration in diabetics. A three-year follow-up study. Angiology 43:490-494, 1992a.

15.

Belcaro G , Bollinger A , Hoffman U , et al (eds): Laser Doppler Flowmetry. London: Med-Orion, 1994.

16.

Bollinger A , Jager K , Geser A , et al : Transcapillary and interstitial diffusion of Na-Fluorescein in chronic venous insufficiency with white atrophy. Int J Microcirc I:5-8, 1982b.

17.

Fagrell B : Microcirculatory disturbances—the final cause for venous leg ulcers? Vasa 11:101-103, 1982.

18.

Fagrell B : Problems using laser Doppler flowmetry on the skin in clinical practice. In: Belcaro G , Hoffman U , Nicolaides AN , et al (eds): Laser Doppler. London: Med Orion, 1994, pp 49-53.

19.

Franzeck U , Bollinger A , Huch R , et al : Transcutaneous oxygen tension and capillary morphologic characteristics and density in patients with chronic venous incompetence. Circulation 70:806-809, 1984.

20.

Hendriksen O : Local reflex in microcirculation in human subcutaneous tissue. Acta Physiol Scand 97:446-449, 1976.

21.

Rayman G , Hassan A , Tooke JE : Blood flow in the skin of the foot related to posture in patients with diabetes mellitus. BMJ 292:87-91, 1986.

22.

Thulesius O : Capillary filtration under normal and pathological conditions. Angiologia 10:198-201, 1973.

23.

Bergan JJ , Schmid-Schonbein GW , Takase S : Therapeutic approach to chronic venous insufficiency and its complications: Place of Daflon 500 mg. Angiology 52(suppl 1):S43-S45, 2001.

24.

Danielsson G , Jungbeck C , Peterson K , et al : A randomized controlled trial of micronized purified flavonoid fraction vs placebo in patients with chronic venous disease. Eur J Vasc Endovasc Surg 23:73-79, 2002.

25.

Belcaro G , Cesarone MR , Bavera P , et al : HR (Venoruton 1000, Paroven, 0-[beta-hydroxyethyl]-rutosides) vs Daflon 500 in chronic venous disease and microangiopathy: An independent prospective, controlled, randomized trial. J Cardiovasc Pharmacol Ther 7:139-145, 2002.

26.

Cesarone MR , Belcaro G , Pellegrini L , et al : HR, 0-(beta-hydroxyethyl)-rutosides, in comparison with diosmin + hesperidin in chronic venous insufficiency and venous microangiopathy: An independent, prospective, comparative registry study. Angiology 56:1-8, 2005.

27.

Belcaro G , Cesarone MR , Ippolito E , et al : Evaluation of quality of life (Ve-QOL) in chronic venous insufficiency and venous disease. AKOM Web J 2:12-15, 2005.

28.

Cesarone MR , Belcaro G , Incandela L , et al : Flight microangiopathy in medium-to-long-distance flights: Prevention of edema and microcirculation alterations with HR (Paroven, Venoruton; 0(beta-hydroxyethyl)-rutosides). J Cardiovasc Pharmacol Ther 7(suppl I):S17-S19, 2002.

29.

Cesarone MR , Incandela L , De Sanctis MT , et al : Variations in plasma free-radicals in patients with venous hypertension with HR (Paroven, Venoruton; 0(beta-hydroxyethyl)-rutosides): A clinical, prospective, placebo-controlled, randomized trial. J Cardiovasc Pharmacol Ther 7(suppl 1):S25-S28, 2002.

30.

Ekestrom S , Welti R : The affinity of hydroxyethyl-rutosides for the venous wall and its efficacy in preventing early occlusion of aorto-coronary vein bypass grafts. Phlebology 5(suppl 1):41-48, 1990.

31.

Beckers C , Zijilstra JA : New aspects of the pathogenesis of CVI and the site of action of Venoruton. Phlebology Digest 14:8-11, 2001.

32.

Nees S , Juchem G , Fink R : Influence of polymorphonuclear leukocytes and platelets on the barrier function of cultured venular endothelial cells. Proceedings of the 6th World Congress for Microcirculation. Bologna: Monduzzi, 1996, pp 401-404.

33.

Roland IH , Bougelet C , Ninane N , et al : Effect of hydroxyethylrutosides on hypoxial-induced neutrophil adherence to umbilical vein endothelium. Cardiovasc Drugs Ther 12:375-381, 1998.